Advertisement

MUC16 mutation is associated with tumor grade, clinical features, and prognosis in glioma patients

      Highlights

      • MUC16 gene is frequently mutated in GBM but not in LGG patients.
      • Mutated-MUC16 in LGG patients is associated with better prognosis.
      • MUC16 mutation in GBM patients is associated with worse prognosis.
      • MUC16 mutation may assist in glioma diagnosis and prognosis.

      Abstract

      MUC16 is a member of the attached mucin family that encodes cancer antigen 125 (CA-125), but the association of MUC16 status with grade and subtypes of glioma patients has not yet been established. Data for MUC16 mRNA expression in 37 different cancer types were considered, and genomic data from the Cancer Genome Atlas (TCGA) from 1051 low-grade glioma (LGG) patients and 833 glioblastoma (GBM) patients were analyzed. LGG and GBM has low expression of MUC16, but it is frequently mutated in GBM. Kaplan-Meier survival analysis, glioma subtypes, methylation, and isocitrate dehydrogenase (IDH1) status were all performed. We found that mutated-MUC16 in LGG patients is associated with better prognosis considering overall survival (OS), IDH1, methylation, 1p/19q, and 10q status. Conversely, MUC16 mutation were related with worse prognosis in GBM patients upon analyzing those same parameters. Therefore, MUC16 mutations may assist in glioma diagnosis and prognosis and should be further studied in this tumor type.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Cancer Genetics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Davis M.E.
        Epidemiology and overview of gliomas.
        Semin Oncol Nurs. 2018; 34: 420-429https://doi.org/10.1016/j.soncn.2018.10.001
        • Louis D.N.
        • Ohgaki H.
        • Wiestler O.D.
        • Cavenee W.K.
        • Burger P.C.
        • Jouvet A.
        • et al.
        The 2007 WHO classification of tumours of the central nervous system.
        Acta Neuropathol. 2007; 114: 97-109https://doi.org/10.1007/s00401-007-0243-4
        • Youland R.S.
        • Schomas D.A.
        • Brown P.D.
        • Nwachukwu C.
        • Buckner J.C.
        • Giannini C.
        • et al.
        Changes in presentation, treatment, and outcomes of adult low-grade gliomas over the past fifty years.
        Neuro Oncol. 2013; 15: 1102-1110https://doi.org/10.1093/neuonc/not080
        • Louis D.N.
        • Perry A.
        • Reifenberger G.
        • von Deimling A.
        • Figarella-Branger D.
        • Cavenee W.K.
        • et al.
        The 2016 world health organization classification of tumors of the central nervous system: a summary.
        Acta Neuropathol. 2016; 131: 803-820https://doi.org/10.1007/s00401-016-1545-1
        • Wang T.J.C.
        • Mehta M.P.
        Low-grade glioma radiotherapy treatment and trials.
        Neurosurg Clin N Am. 2019; 30: 111-118https://doi.org/10.1016/j.nec.2018.08.008
        • Ferrer V.P.
        • Moura Neto V.
        • Mentlein R
        Glioma infiltration and extracellular matrix: key players and modulators.
        Glia. 2018; 66https://doi.org/10.1002/glia.23309
        • Carballo G.B.
        • Ribeiro J.H.
        • Lopes G.P.F.
        • Ferrer V.P.
        • Dezonne R.S.
        • Pereira C.M.
        • et al.
        GANT-61 induces autophagy and apoptosis in glioblastoma cells despite their heterogeneity.
        Cell Mol Neurobiol. 2021; 41: 1227-1244https://doi.org/10.1007/s10571-020-00891-6
        • Omuro A.
        • DeAngelis L.M.
        Glioblastoma and other malignant gliomas: a clinical review.
        JAMA - J Am Med Assoc. 2013; 310: 1842-1850https://doi.org/10.1001/jama.2013.280319
        • Pessoa L.S.
        • Heringer M.
        • Ferrer V.P.
        ctDNA as a cancer biomarker: a broad overview.
        Crit Rev Oncol Hematol. 2020; 155https://doi.org/10.1016/j.critrevonc.2020.103109
        • Louis D.N.
        • Perry A.
        • Wesseling P.
        • Brat D.J.
        • Cree I.A.
        • Figarella-Branger D.
        • et al.
        The 2021 WHO classification of tumors of the central nervous system: a summary.
        Neuro Oncol. 2021; 23: 1231-1251https://doi.org/10.1093/neuonc/noab106
        • Gritsch S.
        • Batchelor T.T.
        • Gonzalez Castro L.N
        Diagnostic, therapeutic, and prognostic implications of the 2021 World Health Organization classification of tumors of the central nervous system.
        Cancer. 2022; 128: 47-58https://doi.org/10.1002/cncr.33918
        • Davies J.R.
        • Kirkham S.
        • Svitacheva N.
        • Thornton D.J.
        • Carlstedt I.
        MUC16 is produced in tracheal surface epithelium and submucosal glands and is present in secretions from normal human airway and cultured bronchial epithelial cells.
        Int J Biochem Cell Biol. 2007; 39: 1943-1954https://doi.org/10.1016/j.biocel.2007.05.013
        • Wang Y.
        • Cheon D.J.
        • Lu Z.
        • Cunningham S.L.
        • Chen C.M.
        • Luo R.Z.
        • et al.
        MUC16 expression during embryogenesis, in adult tissues, and ovarian cancer in the mouse.
        Differentiation. 2008; 76: 1081-1092https://doi.org/10.1111/j.1432-0436.2008.00295.x
        • Xiong L.
        • Woodward A.M.
        • Argüeso P.
        Notch signaling modulates MUC16 biosynthesis in an in vitro model of human corneal and conjunctival epithelial cell differentiation.
        Invest Ophthalmol Vis Sci. 2011; 52: 5641-5646https://doi.org/10.1167/iovs.11-7196
        • Felder M.
        • Kapur A.
        • Gonzalez-Bosquet J.
        • Horibata S.
        • Heintz J.
        • Albrecht R.
        • et al.
        MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress.
        Mol Cancer. 2014; 13: 1-15https://doi.org/10.1186/1476-4598-13-129
        • Hattrup C.L.
        • Gendler S.J.
        Structure and function of the cell surface (tethered) mucins.
        Annu Rev Physiol. 2008; 70: 431-457https://doi.org/10.1146/annurev.physiol.70.113006.100659
        • Blalock T.D.
        • Spurr-Michaud S.J.
        • Tisdale A.S.
        • Gipson I.K.
        Release of membrane-associated mucins from ocular surface epithelia.
        Invest Ophthalmol Vis Sci. 2008; 49: 1864-1871https://doi.org/10.1167/iovs.07-1081
        • Morgado M.
        • Carson D.D.
        PPARγ modulation of cytokine-stimulated MUC16 (CA125) expression in breast and ovarian cancer-derived cells.
        J Cell Biochem. 2017; 118: 163-171https://doi.org/10.1002/jcb.25622
        • Yin B.W.
        • KO Lloyd
        Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16.
        J Biol Chem. 2001; 276: 27371-27375https://doi.org/10.1074/jbc.M103554200
        • Haridas D.
        • Ponnusamy M.P.
        • Chugh S.
        • Lakshmanan I.
        • Seshacharyulu P.
        • Batra S.K.
        MUC16: molecular analysis and its functional implications in benign and malignant conditions.
        FASEB J. 2014; 28: 4183-4199https://doi.org/10.1096/fj.14-257352
        • Reinartz S.
        • Failer S.
        • Schuell T.
        • Wagner U.
        CA125 (MUC16) gene silencing suppresses growth properties of ovarian and breast cancer cells.
        Eur J Cancer. 2012; 48: 1558-1569https://doi.org/10.1016/j.ejca.2011.07.004
        • Morgado M.
        • Sutton M.N.
        • Simmons M.
        • Warren C.R.
        • Lu Z.
        • Constantinou P.E.
        • et al.
        Tumor necrosis factor-α and interferon-γ stimulate MUC16 (CA125) expression in breast, endometrial and ovarian cancers through NFκB.
        Oncotarget. 2016; 7: 14871-14884https://doi.org/10.18632/oncotarget.7652
        • Bottoni P.
        • Scatena R.
        The role of CA 125 as tumor marker: biochemical and clinical aspects.
        Adv Exp Med Biol. 2015; 867: 229-244https://doi.org/10.1007/978-94-017-7215-0_14
        • Zhai Y.
        • Lu Q.
        • Lou T.
        • Cao G.
        • Wang S.
        • Zhang Z.
        affects the biological functions of ovarian cancer cells and induces an antitumor immune response by activating dendritic cells.
        Ann Transl Med. 2020; 8: 1494https://doi.org/10.21037/atm-20-6388
        • Szwedziak K.
        • Szymański D.
        • Strzelczyk J.
        CA 125 concentration in portal blood as a predictor of resectability in pancreatic tumor.
        Contemp Oncol. 2013; 17 (Pozn): 394-399https://doi.org/10.5114/wo.2013.35057
        • Thomas D.
        • Sagar S.
        • Liu X.
        • Lee H.R.
        • Grunkemeyer J.A.
        • Grandgenett P.M.
        • et al.
        Isoforms of MUC16 activate oncogenic signaling through EGF receptors to enhance the progression of pancreatic cancer.
        Mol Ther. 2021; 29: 1557-1571https://doi.org/10.1016/j.ymthe.2020.12.029
        • Hu J.
        • Sun J.
        MUC16 mutations improve patients’ prognosis by enhancing the infiltration and antitumor immunity of cytotoxic T lymphocytes in the endometrial cancer microenvironment.
        Oncoimmunology. 2018; 7e1487914https://doi.org/10.1080/2162402X.2018.1487914
        • Kanwal M.
        • Ding X.J.
        • Song X.
        • Zhou G.B.
        • Cao Y.
        overexpression induced by gene mutations promotes lung cancer cell growth and invasion.
        Oncotarget. 2018; 9: 12226-12239https://doi.org/10.18632/oncotarget.24203
        • Wang X.
        • Yu X.
        • Krauthammer M.
        • Hugo W.
        • Duan C.
        • Kanetsky P.A.
        • et al.
        The association of.
        Cancer Epidemiol Biomarkers Prev. 2020; 29: 1792-1799https://doi.org/10.1158/1055-9965.EPI-20-0307
        • Yang Y.
        • Zhang J.
        • Chen Y.
        • Xu R.
        • Zhao Q.
        • Guo W.
        MUC4, MUC16, and TTN genes mutation correlated with prognosis, and predicted tumor mutation burden and immunotherapy efficacy in gastric cancer and pan-cancer.
        Clin Transl Med. 2020; 10: e155https://doi.org/10.1002/ctm2.155
        • Aithal A.
        • Rauth S.
        • Kshirsagar P.
        • Shah A.
        • Lakshmanan I.
        • Junker W.M.
        • et al.
        MUC16 as a novel target for cancer therapy.
        Expert Opin Ther Targets. 2018; 22: 675-686https://doi.org/10.1080/14728222.2018.1498845
        • Romeijn P.
        • Lenthall R.
        • Stavrou D.
        • Melcher D.
        • Ladyman H.
        • Ritter M.A.
        Identification of glioma-associated antigen MUC 2-63 as CD44.
        Br J Cancer. 1994; 70: 799-803https://doi.org/10.1038/bjc.1994.402
        • Oosterkamp H.M.
        • Scheiner L.
        • Stefanova M.C.
        • Lloyd K.O.
        • Finstad C.L.
        Comparison of MUC-1 mucin expression in epithelial and non-epithelial cancer cell lines and demonstration of a new short variant form (MUC-1/Z).
        Int J Cancer. 1997; 72: 87-94https://doi.org/10.1002/(sici)1097-0215(19970703)72:1<87::aid-ijc13>3.0.co;2-7
        • Hagel C.
        • Neumaier M.
        • Stavrou D.
        Sequencing data of the antiglioma antibody MUC 2-63 and strategy for construction of chimeric antibodies.
        Cell Biophys. 1994; 24–25: 331-339https://doi.org/10.1007/BF02789244
        • Cerami E.
        • Gao J.
        • Dogrusoz U.
        • Gross B.E.
        • Sumer S.O.
        • Aksoy B.A.
        • et al.
        The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.
        Cancer Discov. 2012; 2: 401-404https://doi.org/10.1158/2159-8290.CD-12-0095
        • Gao J.
        • Aksoy B.A.
        • Dogrusoz U.
        • Dresdner G.
        • Gross B.
        • Sumer S.O.
        • et al.
        Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal.
        Sci Signal. 2013; 6: pl1https://doi.org/10.1126/scisignal.2004088
        • Hoadley K.A.
        • Yau C.
        • Hinoue T.
        • Wolf D.M.
        • Lazar A.J.
        • Drill E.
        • et al.
        Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer.
        Cell. 2018; 173 (e6): 291-304https://doi.org/10.1016/j.cell.2018.03.022
        • Ellrott K.
        • Bailey M.H.
        • Saksena G.
        • Covington K.R.
        • Kandoth C.
        • Stewart C.
        • et al.
        Scalable open science approach for mutation calling of tumor exomes using multiple genomic pipelines.
        Cell Syst. 2018; 6 (e7): 271-281https://doi.org/10.1016/j.cels.2018.03.002
        • Taylor A.M.
        • Shih J.
        • Ha G.
        • Gao G.F.
        • Zhang X.
        • Berger A.C.
        • et al.
        Genomic and functional approaches to understanding cancer aneuploidy.
        Cancer Cell. 2018; 33 (e3): 676-689https://doi.org/10.1016/j.ccell.2018.03.007
        • Liu J.
        • Lichtenberg T.
        • Hoadley K.A.
        • Poisson L.M.
        • Lazar A.J.
        • Cherniack A.D.
        • et al.
        An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics.
        Cell. 2018; 173 (e11): 400-416https://doi.org/10.1016/j.cell.2018.02.052
        • Sanchez-Vega F.
        • Mina M.
        • Armenia J.
        • Chatila W.K.
        • Luna A.
        • La K.C.
        • et al.
        Oncogenic signaling pathways in the cancer genome atlas.
        Cell. 2018; 173 (e10): 321-337https://doi.org/10.1016/j.cell.2018.03.035
        • Gao Q.
        • Liang W.W.
        • Foltz S.M.
        • Mutharasu G.
        • Jayasinghe R.G.
        • Cao S.
        • et al.
        Driver fusions and their implications in the development and treatment of human cancers.
        Cell Rep. 2018; 23 (e3): 227-238https://doi.org/10.1016/j.celrep.2018.03.050
        • Bhandari V.
        • Hoey C.
        • Liu L.Y.
        • Lalonde E.
        • Ray J.
        • Livingstone J.
        • et al.
        Molecular landmarks of tumor hypoxia across cancer types.
        Nat Genet. 2019; 51: 308-318https://doi.org/10.1038/s41588-018-0318-2
        • Poore G.D.
        • Kopylova E.
        • Zhu Q.
        • Carpenter C.
        • Fraraccio S.
        • Wandro S.
        • et al.
        Microbiome analyses of blood and tissues suggest cancer diagnostic approach.
        Nature. 2020; 579: 567-574https://doi.org/10.1038/s41586-020-2095-1
        • Ding L.
        • Bailey M.H.
        • Porta-Pardo E.
        • Thorsson V.
        • Colaprico A.
        • Bertrand D.
        • et al.
        Perspective on oncogenic processes at the end of the beginning of cancer genomics.
        Cell. 2018; 173 (e10): 305-320https://doi.org/10.1016/j.cell.2018.03.033
        • Bonneville R.
        • Krook M.A.
        • Kautto E.A.
        • Miya J.
        • Wing M.R.
        • Chen H.Z.
        • et al.
        Landscape of microsatellite instability across 39 cancer types.
        JCO Precis Oncol. 2017; 2017https://doi.org/10.1200/PO.17.00073
        • Johnson B.E.
        • Mazor T.
        • Hong C.
        • Barnes M.
        • Aihara K.
        • McLean C.Y.
        • et al.
        Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma.
        Science (80-). 2014; 343: 189-193https://doi.org/10.1126/science.1239947
        • Ceccarelli M.
        • Barthel F.P.
        • Malta T.M.
        • Sabedot T.S.
        • Salama S.R.
        • Murray B.A.
        • et al.
        Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma.
        Cell. 2016; 164: 550-563https://doi.org/10.1016/j.cell.2015.12.028
        • Zhao J.
        • Chen A.X.
        • Gartrell R.D.
        • Silverman A.M.
        • Aparicio L.
        • Chu T.
        • et al.
        Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma.
        Nat Med. 2019; 25: 462-469https://doi.org/10.1038/s41591-019-0349-y
        • Brennan C.W.
        • Verhaak R.G.
        • McKenna A.
        • Campos B.
        • Noushmehr H.
        • Salama S.R.
        • et al.
        The somatic genomic landscape of glioblastoma.
        Cell. 2013; 155: 462-477https://doi.org/10.1016/j.cell.2013.09.034
        • Network C.G.A.R.
        Comprehensive genomic characterization defines human glioblastoma genes and core pathways.
        Nature. 2008; 455: 1061-1068https://doi.org/10.1038/nature07385
        • Zack T.I.
        • Schumacher S.E.
        • Carter S.L.
        • Cherniack A.D.
        • Saksena G.
        • Tabak B.
        • et al.
        Pan-cancer patterns of somatic copy number alteration.
        Nat Genet. 2013; 45: 1134-1140https://doi.org/10.1038/ng.2760
        • Schwartzbaum J.A.
        • Fisher J.L.
        • Aldape K.D.
        • Wrensch M.
        Epidemiology and molecular pathology of glioma.
        Nat Clin Pr Neurol. 2006; 2 (quiz 1 p following 516): 494-503https://doi.org/10.1038/ncpneuro0289
        • Alghamri M.S.
        • Thalla R.
        • Avvari R.P.
        • Dabaja A.
        • Taher A.
        • Zhao L.
        • et al.
        Tumor mutational burden predicts survival in patients with low-grade gliomas expressing mutated IDH1.
        Neurooncol Adv. 2020; 2 (vdaa042)https://doi.org/10.1093/noajnl/vdaa042
        • Shergalis A.
        • Bankhead A.
        • Luesakul U.
        • Muangsin N.
        • Neamati N.
        Current challenges and opportunities in treating glioblastoma.
        Pharmacol Rev. 2018; 70: 412-445https://doi.org/10.1124/pr.117.014944
        • Chen R.
        • Smith-Cohn M.
        • Cohen A.L.
        • Colman H.
        Glioma subclassifications and their clinical significance.
        Neurotherapeutics. 2017; 14: 284-297https://doi.org/10.1007/s13311-017-0519-x
        • Brat D.J.
        • Verhaak R.G.
        • Aldape K.D.
        • Yung W.K.
        • Salama S.R.
        • Cooper L.A.
        • et al.
        Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas.
        N Engl J Med. 2015; 372: 2481-2498https://doi.org/10.1056/NEJMoa1402121
        • Eckel-Passow J.E.
        • Lachance D.H.
        • Molinaro A.M.
        • Walsh K.M.
        • Decker P.A.
        • Sicotte H.
        • et al.
        Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors.
        N Engl J Med. 2015; 372: 2499-2508https://doi.org/10.1056/NEJMoa1407279
        • Fan K.
        • Yang C.
        • Fan Z.
        • Huang Q.
        • Zhang Y.
        • Cheng H.
        • et al.
        MUC16 C terminal-induced secretion of tumor-derived IL-6 contributes to tumor-associated Treg enrichment in pancreatic cancer.
        Cancer Lett. 2018; 418: 167-175https://doi.org/10.1016/j.canlet.2018.01.017
        • Shen H.
        • Guo M.
        • Wang L.
        • Cui X.
        MUC16 facilitates cervical cancer progression via JAK2/STAT3 phosphorylation-mediated cyclooxygenase-2 expression.
        Genes Genom. 2020; 42: 127-133https://doi.org/10.1007/s13258-019-00885-9
        • Lakshmanan I.
        • Salfity S.
        • Seshacharyulu P.
        • Rachagani S.
        • Thomas A.
        • Das S.
        • et al.
        MUC16 regulates TSPYL5 for lung cancer cell growth and chemoresistance by suppressing p53.
        Clin Cancer Res. 2017; 23: 3906-3917https://doi.org/10.1158/1078-0432.CCR-16-2530
        • Fan K.
        • Zhang D.
        • Li M.
        • Shen S.
        • Wang J.
        • Ni X.
        • et al.
        Carboxyl-terminal polypeptide fragment of MUC16 combing stathmin1 promotes gallbladder cancer cell migration and invasion.
        Med Oncol. 2020; 37: 114https://doi.org/10.1007/s12032-020-01438-x
        • Coelho R.
        • Marcos-Silva L.
        • Ricardo S.
        • Ponte F.
        • Costa A.
        • Lopes J.M.
        • et al.
        Peritoneal dissemination of ovarian cancer: role of MUC16-mesothelin interaction and implications for treatment.
        Expert Rev Anticancer Ther. 2018; 18: 177-186https://doi.org/10.1080/14737140.2018.1418326
        • Zhang M.
        • Cheng S.
        • Jin Y.
        • Zhao Y.
        • Wang Y.
        Roles of CA125 in diagnosis, prediction, and oncogenesis of ovarian cancer.
        Biochim Biophys Acta Rev Cancer. 2021; 1875188503https://doi.org/10.1016/j.bbcan.2021.188503
        • Kim N.
        • Hong Y.
        • Kwon D.
        • Yoon S.
        Somatic mutaome profile in human cancer tissues.
        Genomics Inf. 2013; 11: 239-244https://doi.org/10.5808/GI.2013.11.4.239
        • Ma F.
        • Laster K.
        • Nie W.
        • Liu F.
        • Kim D.J.
        • Lee M.H.
        • et al.
        Heterogeneity analysis of esophageal squamous cell carcinoma in cell lines, tumor tissues and patient-derived Xenografts.
        J Cancer. 2021; 12: 3930-3944https://doi.org/10.7150/jca.52286
        • Shimizu A.
        • Hirono S.
        • Tani M.
        • Kawai M.
        • Okada K.
        • Miyazawa M.
        • et al.
        Coexpression of MUC16 and mesothelin is related to the invasion process in pancreatic ductal adenocarcinoma.
        Cancer Sci. 2012; 103: 739-746https://doi.org/10.1111/j.1349-7006.2012.02214.x
        • Chen S.H.
        • Hung W.C.
        • Wang P.
        • Paul C.
        • Konstantopoulos K.
        Mesothelin binding to CA125/MUC16 promotes pancreatic cancer cell motility and invasion via MMP-7 activation.
        Sci Rep. 2013; 3: 1870https://doi.org/10.1038/srep01870
        • Das S.
        • Rachagani S.
        • Torres-Gonzalez M.P.
        • Lakshmanan I.
        • Majhi P.D.
        • Smith L.M.
        • et al.
        Carboxyl-terminal domain of MUC16 imparts tumorigenic and metastatic functions through nuclear translocation of JAK2 to pancreatic cancer cells.
        Oncotarget. 2015; 6: 5772-5787https://doi.org/10.18632/oncotarget.3308
        • Rao T.D.
        • Tian H.
        • Ma X.
        • Yan X.
        • Thapi S.
        • Schultz N.
        • et al.
        Expression of the carboxy-terminal portion of MUC16/CA125 induces transformation and tumor invasion.
        PLoS One. 2015; 10e0126633https://doi.org/10.1371/journal.pone.0126633
        • Liang C.
        • Qin Y.
        • Zhang B.
        • Ji S.
        • Shi S.
        • Xu W.
        • et al.
        Oncogenic KRAS targets MUC16/CA125 in pancreatic ductal adenocarcinoma.
        Mol Cancer Res. 2017; 15: 201-212https://doi.org/10.1158/1541-7786.MCR-16-0296
        • Liu J.
        • Li L.
        • Luo N.
        • Liu Q.
        • Liu L.
        • Chen D.
        • et al.
        Inflammatory signals induce MUC16 expression in ovarian cancer cells via NF-κB activation.
        Exp Ther Med. 2021; 21: 163https://doi.org/10.3892/etm.2020.9594
        • Kaneko O.
        • Gong L.
        • Zhang J.
        • Hansen J.K.
        • Hassan R.
        • Lee B.
        • et al.
        A binding domain on mesothelin for CA125/MUC16.
        J Biol Chem. 2009; 284: 3739-3749https://doi.org/10.1074/jbc.M806776200
        • Yang W.B.
        • Li C.Y.
        Correlations of MUC15 overexpression with clinicopathological features and prognosis of glioma.
        J Huazhong Univ Sci Technol Med Sci. 2014; 34: 254-259https://doi.org/10.1007/s11596-014-1267-3
        • Xiao G.
        • Zhang X.
        • Chen Y.
        • Xia Z.
        • Cao H.
        • Huang J.
        • et al.
        Aging-related genes are potential prognostic biomarkers for patients with gliomas.
        Aging. 2021; 13 (Albany NY): 13239-13263https://doi.org/10.18632/aging.203008
        • Yang C.
        • Tan Y.
        • Li S.
        • Zhou J.
        • Wang Q.
        • Wang Y.
        • et al.
        Genomic landscapes by multiregion sequencing combined with circulation tumor DNA detection contribute to molecular diagnosis in glioblastomas.
        Aging. 2019; 11 (Albany NY): 11224-11243https://doi.org/10.18632/aging.102526
        • Zhang L.
        • Han X.
        • Shi Y.
        Association of MUC16 mutation with response to immune checkpoint inhibitors in solid tumors.
        JAMA Netw Open. 2020; 3e2013201https://doi.org/10.1001/jamanetworkopen.2020.13201
        • Li X.
        • Pasche B.
        • Zhang W.
        • Chen K.
        Association of MUC16 mutation with tumor mutation load and outcomes in patients with gastric cancer.
        JAMA Oncol. 2018; 4: 1691-1698https://doi.org/10.1001/jamaoncol.2018.2805
        • Kim S.W.
        • Kim J.B.
        • Kim J.H.
        • Lee J.K.
        Interferon-gamma-induced expressions of heat shock protein 60 and heat shock protein 10 in C6 astroglioma cells: identification of the signal transducers and activators of transcription 3-binding site in bidirectional promoter.
        Neuroreport. 2007; 18: 385-389https://doi.org/10.1097/WNR.0b013e32801299cc
        • Selagea L.
        • Mishra A.
        • Anand M.
        • Ross J.
        • Tucker-Burden C.
        • Kong J.
        • et al.
        EGFR and C/EBP-β oncogenic signaling is bidirectional in human glioma and varies with the C/EBP-β isoform.
        FASEB J. 2016; 30: 4098-4108https://doi.org/10.1096/fj.201600550R
        • Wang W.
        • Lu Z.
        • Wang M.
        • Liu Z.
        • Wu B.
        • Yang C.
        • et al.
        The cuproptosis-related signature associated with the tumor environment and prognosis of patients with glioma.
        Front Immunol. 2022; 13998236https://doi.org/10.3389/fimmu.2022.998236
        • Sun H.
        • Yin L.
        • Li S.
        • Han S.
        • Song G.
        • Liu N.
        • et al.
        Prognostic significance of IDH mutation in adult low-grade gliomas: a meta-analysis.
        J Neurooncol. 2013; 113: 277-284https://doi.org/10.1007/s11060-013-1107-5
        • Khan I.
        • Waqas M.
        • Shamim M.S.
        Prognostic significance of IDH 1 mutation in patients with glioblastoma multiforme.
        J Pak Med Assoc. 2017; 67: 816-817
        • Wick W.
        • Hartmann C.
        • Engel C.
        • Stoffels M.
        • Felsberg J.
        • Stockhammer F.
        • et al.
        NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
        J Clin Oncol. 2009; 27: 5874-5880https://doi.org/10.1200/JCO.2009.23.6497
        • Lv L.
        • Zhang Y.
        • Zhao Y.
        • Wei Q.
        • Zhao Y.
        • Yi Q.
        Effects of 1p/19q codeletion on immune phenotype in low grade glioma.
        Front Cell Neurosci. 2021; 15: 1-18https://doi.org/10.3389/fncel.2021.704344
        • Li F.
        • He X.
        • Ye D.
        • Lin Y.
        • Yu H.
        • Yao C.
        • et al.
        NADP(+)-IDH mutations promote hypersuccinylation that impairs mitochondria respiration and induces apoptosis resistance.
        Mol Cell. 2015; 60: 661-675https://doi.org/10.1016/j.molcel.2015.10.017
        • Wang X.
        • Liu R.
        • Qu X.
        • Yu H.
        • Chu H.
        • Zhang Y.
        • et al.
        α-Ketoglutarate-activated NF-κB signaling promotes compensatory glucose uptake and brain tumor development.
        Mol Cell. 2019; 76 (e7): 148-162https://doi.org/10.1016/j.molcel.2019.07.007
        • Hegi M.E.
        • Diserens A.C.
        • Gorlia T.
        • Hamou M.F.
        • de Tribolet N.
        • Weller M.
        • et al.
        MGMT gene silencing and benefit from temozolomide in glioblastoma.
        N Engl J Med. 2005; 352: 997-1003https://doi.org/10.1056/NEJMoa043331
        • Wick W.
        • Weller M.
        • van den Bent M.
        • Sanson M.
        • Weiler M.
        • von Deimling A.
        • et al.
        MGMT testing–the challenges for biomarker-based glioma treatment.
        Nat Rev Neurol. 2014; 10: 372-385https://doi.org/10.1038/nrneurol.2014.100
        • Hegi M.E.
        • Diserens A.C.
        • Godard S.
        • Dietrich P.Y.
        • Regli L.
        • Ostermann S.
        • et al.
        Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide.
        Clin Cancer Res. 2004; 10: 1871-1874https://doi.org/10.1158/1078-0432.ccr-03-0384
        • Fontana L.
        • Tabano S.
        • Bonaparte E.
        • Marfia G.
        • Pesenti C.
        • Falcone R.
        • et al.
        MGMT-methylated alleles are distributed heterogeneously within glioma samples irrespective of IDH status and chromosome 10q deletion.
        J Neuropathol Exp Neurol. 2016; 75: 791-800https://doi.org/10.1093/jnen/nlw052
        • Stupp R.
        • Hegi M.E.
        • Mason W.P.
        • van den Bent M.J.
        • Taphoorn M.J.
        • Janzer R.C.
        • et al.
        Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
        Lancet Oncol. 2009; 10: 459-466https://doi.org/10.1016/S1470-2045(09)70025-7
        • van Thuijl H.F.
        • Scheinin I.
        • Sie D.
        • Alentorn A.
        • van Essen H.F.
        • Cordes M.
        • et al.
        Spatial and temporal evolution of distal 10q deletion, a prognostically unfavorable event in diffuse low-grade gliomas.
        Genome Biol. 2014; 15: 471https://doi.org/10.1186/s13059-014-0471-6
        • Sanson M.
        • Leuraud P.
        • Aguirre-Cruz L.
        • He J.
        • Marie Y.
        • Cartalat-Carel S.
        • et al.
        Analysis of loss of chromosome 10q, DMBT1 homozygous deletions, and PTEN mutations in oligodendrogliomas.
        J Neurosurg. 2002; 97: 1397-1401https://doi.org/10.3171/jns.2002.97.6.1397
        • Fontana L.
        • Tabano S.
        • Bonaparte E.
        • Marfia G.
        • Pesenti C.
        • Falcone R.
        • Augello C.
        • Carlessi N.
        • Silipigni R.
        • Guerneri S.
        • et al.
        MGMT-Methylated Alleles Are Distributed Heterogeneously Within Glioma Samples Irrespective of IDH Status and Chromosome 10q Deletion.
        J Neuropathol Exp Neurol. 2016; 75: 791-800https://doi.org/10.1093/jnen/nlw052